ArticleCNS drugs2022

Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.

Jai Perumal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.